Navigation Links
YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
Date:9/17/2009

    YM Enrolls First Patients in Multinational Randomized, Double-Blind Brain
    Metastases Trial

MISSISSAUGA, Sept. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico. YM BioSciences also announced that it has enrolled the first two patients in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from non-small-cell lung cancer (NSCLC).

"Mexico is the 21st country to have approved nimotuzumab for marketing and, while YM's license for major market territories for nimotuzumab does not include Mexico, this approval reflects the growing recognition throughout much of the world of the value to patients of our drug and the progress being made in its commercialization," said David Allan, Chairman and CEO of YM BioSciences. "As part of YM's registration strategy for nimotuzumab, we were also pleased to report the opening of this second of two randomized, double-blind trials that YM is conducting in Canada and which are both now being expanded internationally."

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and developed at the Center of Molecular Immunology in Cuba. Nimotuzumab is approved in two of the countries in YM's territories. The drug has demonstrated efficacy in clinical trials without producing the numerous and severe toxicities observed with the other marketed EGFR-targeting drugs. Mexican regulatory authorities have approved nimotuzumab for the treat
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Secures Committed Equity Financing Facility
4. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
5. Cell Biosciences Signs Agreement to Acquire Alpha Innotech
6. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
7. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
8. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
9. SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies
10. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
11. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched ... tinnitus. Patients listen to sound therapy that is tailor-made ... weeks to months, their tinnitus volume decreases. , AudioNotch has ... and Notched White Noise. Now, AudioNotch is pleased to announce ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... ArborGen, LLC, a leader in forest tree ... field trials that are utilizing technology in-licensed from Senesco ... The two companies had previously announced that trees that ... in 3-year-old field trials. , , Selected ...
... published in July 7, 2009 Issue of Proceedings of the ... QUEBEC CITY, July 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... focused on endocrine therapy and oncology, today announced publication in ... of Sciences (PNAS), of new data supporting the use of ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... treatments for human disease, announced today that it has initiated ... , the company,s oral drug candidate for managing gastrointestinal symptoms ... is designed to reduce serotonin production in patients with metastatic ...
Cached Biology Technology:ArborGen and Senesco Announce Wood Quality Results 2ArborGen and Senesco Announce Wood Quality Results 3ArborGen and Senesco Announce Wood Quality Results 4AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 2AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 3AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 4Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 2Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 3Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 4
(Date:4/23/2014)... new study from the Indiana University School of Public ... and heart disease by finding a strong association between ... coronary heart disease. , The study found that heme ... by 57 percent, while no association was found between ... sources, and coronary heart disease. , The study was ...
(Date:4/23/2014)... and Spanish . ... released its Conservation Assessment for the Big Bend-Ro Bravo ... 29 priority conservation areas in a region straddling the ... in the states of Texas, Coahuila, and Chihuahua. This ... inhabited by rare and endangered plants and animals, and ...
(Date:4/23/2014)... evidence that the source of a unique rhythmic sound, ... the "bio-duck," is the Antarctic minke whale ( Balaenoptera ... in the 1960s who thought it sounded like a ... locations in the Southern Ocean, but its source has ... an international team of researchers deployed acoustic tags on ...
Breaking Biology News(10 mins):Study: Iron consumption can increase risk for heart disease 2Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... YORK, NY and PALO ALTO, CA January 22, 2009 ... four young scientists with novel approaches to fighting cancer have ... of $450,000 over three years is awarded each year to ... have a major impact on the prevention, diagnosis and treatment ...
... 22, 2009--Biotechnology companies are building on what they ... decade and are expected to drive this market ... Genetic Engineering and Biotechnology News ( GEN ... number of advantages, including reducing reagent consumption, increasing ...
... three-year study to conserve and restore endangered horse mussel ... the University,s marine research and outreach centre in Portaferry ... of Biological Sciences, will provide scientific and technological research ... to restore it. Horse mussel reefs are important ...
Cached Biology News:2009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 22009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 32009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 4GEN reports on growing reliance on microfluidics technology 2Queen's University Belfast works to save Strangford horse mussels 2
B2-Microgloulin...
... utilizies CTI Molecular Imaging's proprietary Focus™ detector ... volume as the R4. The microPET ... any commerically avaiable PET scanner. Focus ... of any scinitallor based PETsystems. The ...
...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: